Haverford Trust Co Has $194.66 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Haverford Trust Co trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,201,143 shares of the company’s stock after selling 8,972 shares during the quarter. Johnson & Johnson accounts for 1.9% of Haverford Trust Co’s holdings, making the stock its 20th biggest holding. Haverford Trust Co’s holdings in Johnson & Johnson were worth $194,657,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Victory Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 2.5% during the 3rd quarter. Victory Capital Management Inc. now owns 2,660,488 shares of the company’s stock worth $431,159,000 after purchasing an additional 64,256 shares in the last quarter. Aptus Capital Advisors LLC boosted its stake in Johnson & Johnson by 40.2% in the third quarter. Aptus Capital Advisors LLC now owns 146,563 shares of the company’s stock valued at $23,752,000 after buying an additional 42,059 shares in the last quarter. Commonwealth Retirement Investments LLC boosted its stake in Johnson & Johnson by 1.8% in the third quarter. Commonwealth Retirement Investments LLC now owns 48,898 shares of the company’s stock valued at $7,924,000 after buying an additional 870 shares in the last quarter. Cumberland Partners Ltd boosted its stake in Johnson & Johnson by 117.6% in the third quarter. Cumberland Partners Ltd now owns 15,450 shares of the company’s stock valued at $2,504,000 after buying an additional 8,350 shares in the last quarter. Finally, Savvy Advisors Inc. boosted its stake in Johnson & Johnson by 107.0% in the third quarter. Savvy Advisors Inc. now owns 9,014 shares of the company’s stock valued at $1,461,000 after buying an additional 4,659 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the company. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Trading Down 1.5 %

Shares of JNJ stock opened at $152.64 on Wednesday. The company has a market cap of $367.50 billion, a P/E ratio of 22.09, a PEG ratio of 2.75 and a beta of 0.53. The stock has a 50 day simple moving average of $162.10 and a two-hundred day simple moving average of $156.01. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.66 earnings per share. Research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.